328 related articles for article (PubMed ID: 28631217)
1. 24-Month Open-Label Teriparatide Once-Weekly Efficacy Research Trial Examining Bone Mineral Density in Subjects with Primary Osteoporosis and High Fracture Risk.
Sugimoto T; Shiraki M; Fukunaga M; Hagino H; Sone T; Nakano T; Kishimoto H; Ito M; Yoshikawa H; Kishida M; Irie C; Nakamura T
Adv Ther; 2017 Jul; 34(7):1727-1740. PubMed ID: 28631217
[TBL] [Abstract][Full Text] [Related]
2. Vertebral fracture risk after once-weekly teriparatide injections: follow-up study of Teriparatide Once-Weekly Efficacy Research (TOWER) trial.
Sugimoto T; Shiraki M; Nakano T; Kishimoto H; Ito M; Fukunaga M; Hagino H; Sone T; Kuroda T; Nakamura T
Curr Med Res Opin; 2013 Mar; 29(3):195-203. PubMed ID: 23259702
[TBL] [Abstract][Full Text] [Related]
3. Randomized Teriparatide [human parathyroid hormone (PTH) 1-34] Once-Weekly Efficacy Research (TOWER) trial for examining the reduction in new vertebral fractures in subjects with primary osteoporosis and high fracture risk.
Nakamura T; Sugimoto T; Nakano T; Kishimoto H; Ito M; Fukunaga M; Hagino H; Sone T; Yoshikawa H; Nishizawa Y; Fujita T; Shiraki M
J Clin Endocrinol Metab; 2012 Sep; 97(9):3097-106. PubMed ID: 22723322
[TBL] [Abstract][Full Text] [Related]
4. Study of twice-weekly injections of Teriparatide by comparing efficacy with once-weekly injections in osteoporosis patients: the TWICE study.
Sugimoto T; Shiraki M; Fukunaga M; Kishimoto H; Hagino H; Sone T; Nakano T; Ito M; Yoshikawa H; Minamida T; Tsuruya Y; Nakamura T
Osteoporos Int; 2019 Nov; 30(11):2321-2331. PubMed ID: 31392401
[TBL] [Abstract][Full Text] [Related]
5. A multicenter, randomized, rater-blinded, parallel-group, phase 3 study to compare the efficacy, safety, and immunogenicity of biosimilar RGB-10 and reference once-daily teriparatide in patients with osteoporosis.
Hagino H; Narita R; Yokoyama Y; Watanabe M; Tomomitsu M
Osteoporos Int; 2019 Oct; 30(10):2027-2037. PubMed ID: 31243480
[TBL] [Abstract][Full Text] [Related]
6. Once-weekly teriparatide in hemodialysis patients with hypoparathyroidism and low bone mass: a prospective study.
Sumida K; Ubara Y; Hoshino J; Mise K; Hayami N; Suwabe T; Kawada M; Imafuku A; Hiramatsu R; Hasegawa E; Yamanouchi M; Sawa N; Takaichi K
Osteoporos Int; 2016 Apr; 27(4):1441-1450. PubMed ID: 26525045
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of once-weekly teriparatide in patients with glucocorticoid-induced osteoporosis: the TOWER-GO study.
Tanaka I; Tanaka Y; Soen S; Oshima H
J Bone Miner Metab; 2021 May; 39(3):446-455. PubMed ID: 33211212
[TBL] [Abstract][Full Text] [Related]
8. Treatment responses with once-weekly teriparatide therapy for osteoporosis.
Shiraki M; Ueda S; Sugimoto T; Kuroda T; Nakamura T
Osteoporos Int; 2016 Oct; 27(10):3057-62. PubMed ID: 27234671
[TBL] [Abstract][Full Text] [Related]
9. Effect of Abaloparatide vs Placebo on New Vertebral Fractures in Postmenopausal Women With Osteoporosis: A Randomized Clinical Trial.
Miller PD; Hattersley G; Riis BJ; Williams GC; Lau E; Russo LA; Alexandersen P; Zerbini CA; Hu MY; Harris AG; Fitzpatrick LA; Cosman F; Christiansen C;
JAMA; 2016 Aug; 316(7):722-33. PubMed ID: 27533157
[TBL] [Abstract][Full Text] [Related]
10. Once-weekly teriparatide reduces the risk of vertebral fracture in patients with various fracture risks: subgroup analysis of the Teriparatide Once-Weekly Efficacy Research (TOWER) trial.
Nakano T; Shiraki M; Sugimoto T; Kishimoto H; Ito M; Fukunaga M; Hagino H; Sone T; Kuroda T; Nakamura T
J Bone Miner Metab; 2014 Jul; 32(4):441-6. PubMed ID: 24213216
[TBL] [Abstract][Full Text] [Related]
11. [Once-weekly teriparatide treatment on osteoporosis].
Nakano T
Clin Calcium; 2014 Jan; 24(1):100-5. PubMed ID: 24369286
[TBL] [Abstract][Full Text] [Related]
12. Changes in bone mineral density, bone turnover markers, and vertebral fracture risk reduction with once weekly teriparatide.
Tanaka S; Kuroda T; Sugimoto T; Nakamura T; Shiraki M
Curr Med Res Opin; 2014 May; 30(5):931-6. PubMed ID: 24392946
[TBL] [Abstract][Full Text] [Related]
13. A randomized, controlled trial of once-weekly teriparatide injection versus alendronate in patients at high risk of osteoporotic fracture: primary results of the Japanese Osteoporosis Intervention Trial-05.
Hagino H; Sugimoto T; Tanaka S; Sasaki K; Sone T; Nakamura T; Soen S; Mori S
Osteoporos Int; 2021 Nov; 32(11):2301-2311. PubMed ID: 34002252
[TBL] [Abstract][Full Text] [Related]
14. Assessing the Effects of Teriparatide Treatment on Bone Mineral Density, Bone Microarchitecture, and Bone Strength.
Kleerekoper M; Greenspan SL; Lewiecki EM; Miller PD; Kendler DL; Maricic M; Keaveny TM; Kopperdahl DL; Ruff VA; Wan X; Janos B; Krohn K
J Bone Joint Surg Am; 2014 Jun; 96(11):e90. PubMed ID: 24897747
[TBL] [Abstract][Full Text] [Related]
15. Teriparatide or alendronate in glucocorticoid-induced osteoporosis.
Saag KG; Shane E; Boonen S; Marín F; Donley DW; Taylor KA; Dalsky GP; Marcus R
N Engl J Med; 2007 Nov; 357(20):2028-39. PubMed ID: 18003959
[TBL] [Abstract][Full Text] [Related]
16. Response rate of bone mineral density to teriparatide in postmenopausal women with osteoporosis.
Gallagher JC; Rosen CJ; Chen P; Misurski DA; Marcus R
Bone; 2006 Dec; 39(6):1268-75. PubMed ID: 16884968
[TBL] [Abstract][Full Text] [Related]
17. Effects of teriparatide on bone mineral density and bone turnover markers in Japanese subjects with osteoporosis at high risk of fracture in a 24-month clinical study: 12-month, randomized, placebo-controlled, double-blind and 12-month open-label phases.
Miyauchi A; Matsumoto T; Sugimoto T; Tsujimoto M; Warner MR; Nakamura T
Bone; 2010 Sep; 47(3):493-502. PubMed ID: 20580870
[TBL] [Abstract][Full Text] [Related]
18. Renal Phosphate Reabsorption is Correlated with the Increase in Lumbar Bone Mineral Density in Patients Receiving Once-Weekly Teriparatide.
Takeuchi Y; Kuroda T; Sugimoto T; Shiraki M; Nakamura T
Calcif Tissue Int; 2016 Feb; 98(2):186-92. PubMed ID: 26478225
[TBL] [Abstract][Full Text] [Related]
19. Effects of intravenous zoledronic acid plus subcutaneous teriparatide [rhPTH(1-34)] in postmenopausal osteoporosis.
Cosman F; Eriksen EF; Recknor C; Miller PD; Guañabens N; Kasperk C; Papanastasiou P; Readie A; Rao H; Gasser JA; Bucci-Rechtweg C; Boonen S
J Bone Miner Res; 2011 Mar; 26(3):503-11. PubMed ID: 20814967
[TBL] [Abstract][Full Text] [Related]
20. Achieving osteoporosis treat-to-target goals with teriparatide or alendronate: sub-analysis of Japanese Osteoporosis Intervention Trial-05 (JOINT-05).
Hagino H; Tanaka S; Kuroda T; Mori S; Soen S
J Bone Miner Metab; 2024 May; 42(3):382-388. PubMed ID: 38755328
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
